UniProt ID | IRF3_MOUSE | |
---|---|---|
UniProt AC | P70671 | |
Protein Name | Interferon regulatory factor 3 | |
Gene Name | Irf3 | |
Organism | Mus musculus (Mouse). | |
Sequence Length | 419 | |
Subcellular Localization | Cytoplasm . Nucleus . Shuttles between cytoplasmic and nuclear compartments, with export being the prevailing effect. When activated, IRF3 interaction with CREBBP prevents its export to the cytoplasm. | |
Protein Description | Key transcriptional regulator of type I interferon (IFN)-dependent immune responses which plays a critical role in the innate immune response against DNA and RNA viruses. Regulates the transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element (ISRE) in their promoters. Acts as a more potent activator of the IFN-beta (IFNB) gene than the IFN-alpha (IFNA) gene and plays a critical role in both the early and late phases of the IFNA/B gene induction. Found in an inactive form in the cytoplasm of uninfected cells and following viral infection, double-stranded RNA (dsRNA), or toll-like receptor (TLR) signaling, is phosphorylated by IKBKE and TBK1 kinases. This induces a conformational change, leading to its dimerization and nuclear localization and association with CREB binding protein (CREBBP) to form dsRNA-activated factor 1 (DRAF1), a complex which activates the transcription of the type I IFN and ISG genes. Can activate distinct gene expression programs in macrophages and can induce significant apoptosis in primary macrophages.. | |
Protein Sequence | METPKPRILPWLVSQLDLGQLEGVAWLDESRTRFRIPWKHGLRQDAQMADFGIFQAWAEASGAYTPGKDKPDVSTWKRNFRSALNRKEVLRLAADNSKDPYDPHKVYEFVTPGARDFVHLGASPDTNGKSSLPHSQENLPKLFDGLILGPLKDEGSSDLAIVSDPSQQLPSPNVNNFLNPAPQENPLKQLLAEEQWEFEVTAFYRGRQVFQQTLFCPGGLRLVGSTADMTLPWQPVTLPDPEGFLTDKLVKEYVGQVLKGLGNGLALWQAGQCLWAQRLGHSHAFWALGEELLPDSGRGPDGEVHKDKDGAVFDLRPFVADLIAFMEGSGHSPRYTLWFCMGEMWPQDQPWVKRLVMVKVVPTCLKELLEMAREGGASSLKTVDLHISNSQPISLTSDQYKAYLQDLVEDMDFQATGNI | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
3 | Phosphorylation | -----METPKPRILP -----CCCCCCCCHH | 35.00 | - | |
14 | Phosphorylation | RILPWLVSQLDLGQL CCHHHHHHHCCCCCC | 23.90 | - | |
74 | Phosphorylation | GKDKPDVSTWKRNFR CCCCCCHHHHHHHHH | 35.61 | 25338131 | |
75 | Phosphorylation | KDKPDVSTWKRNFRS CCCCCHHHHHHHHHH | 34.55 | - | |
77 | Malonylation | KPDVSTWKRNFRSAL CCCHHHHHHHHHHHH | 37.24 | 26320211 | |
87 | Ubiquitination | FRSALNRKEVLRLAA HHHHHCHHHHHHHHH | 51.61 | - | |
97 | Phosphorylation | LRLAADNSKDPYDPH HHHHHCCCCCCCCHH | 38.70 | - | |
105 | Acetylation | KDPYDPHKVYEFVTP CCCCCHHHHEEEECC | 52.48 | 23954790 | |
105 | Malonylation | KDPYDPHKVYEFVTP CCCCCHHHHEEEECC | 52.48 | 26320211 | |
107 | Phosphorylation | PYDPHKVYEFVTPGA CCCHHHHEEEECCCC | 14.41 | 25367039 | |
111 | Phosphorylation | HKVYEFVTPGARDFV HHHEEEECCCCCCCE | 22.71 | 23984901 | |
123 | Phosphorylation | DFVHLGASPDTNGKS CCEECCCCCCCCCCC | 22.85 | 25521595 | |
126 | Phosphorylation | HLGASPDTNGKSSLP ECCCCCCCCCCCCCC | 49.62 | 21082442 | |
130 | Phosphorylation | SPDTNGKSSLPHSQE CCCCCCCCCCCCCCC | 38.21 | 27087446 | |
131 | Phosphorylation | PDTNGKSSLPHSQEN CCCCCCCCCCCCCCC | 49.78 | 27087446 | |
135 | Phosphorylation | GKSSLPHSQENLPKL CCCCCCCCCCCHHHH | 36.93 | 27087446 | |
152 | Sumoylation | GLILGPLKDEGSSDL CEEEECCCCCCCCCE | 57.79 | - | |
152 | Sumoylation | GLILGPLKDEGSSDL CEEEECCCCCCCCCE | 57.79 | - | |
171 | Phosphorylation | DPSQQLPSPNVNNFL CHHHCCCCCCCCCCC | 37.38 | 30352176 | |
230 | Phosphorylation | VGSTADMTLPWQPVT ECEECCEECCCCCCC | 30.16 | - | |
237 | Phosphorylation | TLPWQPVTLPDPEGF ECCCCCCCCCCCCCC | 38.98 | - | |
246 | Phosphorylation | PDPEGFLTDKLVKEY CCCCCCCCHHHHHHH | 28.91 | - | |
332 | Phosphorylation | FMEGSGHSPRYTLWF HHHCCCCCCCCEEEE | 18.01 | - | |
366 | Ubiquitination | KVVPTCLKELLEMAR HHHHHHHHHHHHHHH | 48.76 | 22790023 | |
378 | Phosphorylation | MAREGGASSLKTVDL HHHHCCCCCCEEEEE | 39.21 | 30352176 | |
379 | Phosphorylation | AREGGASSLKTVDLH HHHCCCCCCEEEEEE | 33.09 | 27149854 | |
382 | Phosphorylation | GGASSLKTVDLHISN CCCCCCEEEEEEECC | 25.25 | 24719451 | |
388 | Phosphorylation | KTVDLHISNSQPISL EEEEEEECCCCCCCC | 21.49 | 28725479 | |
390 | Phosphorylation | VDLHISNSQPISLTS EEEEECCCCCCCCCH | 30.46 | - | |
396 | Phosphorylation | NSQPISLTSDQYKAY CCCCCCCCHHHHHHH | 24.38 | 21106850 |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of IRF3_MOUSE !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of IRF3_MOUSE !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
TRI26_MOUSE | Trim26 | physical | 25763818 |
Kegg Drug | ||||||
---|---|---|---|---|---|---|
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Solid tumor proteome and phosphoproteome analysis by high resolutionmass spectrometry."; Zanivan S., Gnad F., Wickstroem S.A., Geiger T., Macek B., Cox J.,Faessler R., Mann M.; J. Proteome Res. 7:5314-5326(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-123 AND SER-135, ANDMASS SPECTROMETRY. |